Exclusive QED product greatly enhances antibody production

Newly patented cell culture medium boosts production up to 25 times over conventional technology

QED Bioscience, Inc. holds the exclusive international license on a newly patented cell culture medium that boosts antibody production five to 25 times over conventional products.

The cell culture medium, created by Exploit Technologies of Singapore, has been issued U.S. Patent #7,601,531. QED Bioscience currently uses it to greatly enhance production of monoclonal antibodies and recombinant proteins. Efficiencies facilitated by the technology lower production costs, allowing QED to pass the savings along to its customers. The product will be available via QED's online catalog in 2010.

"The beautiful part of this technology is that once you set up production cultures, very little additional attention is required," said Eileen Skaletsky, President of QED Bioscience. "Production is much less labor-intensive and it eliminates the risk of contamination that comes with replacing the medium or relocating the culture."

Skaletsky also pointed out that the technology is an excellent solution for organizations responding to an increasing sensitivity to using animals in science laboratories for antibody production. It also eliminates the presence of animal-derived proteins during production that could be problematic.

"The technology has worked incredibly well for us," Skaletsky said. "We use it for our clients and often they're so thrilled with the results they want to buy it from us. We're making every effort to make that possible as soon as we can."

-###-

About QED Bioscience, Inc.
QED Bioscience has been designing and manufacturing antibodies for over 20 years. Throughout the company's history, its goals have remained unchanged: provide the best antibody products and services on the market and support clients with the expertise and assistance they should expect from a full-spectrum antibody company like QED. QED is located in San Diego, Calif., the single most important market worldwide for antibody engineering in preclinical research. 

About Exploit Technologies
Exploit Technologies, the strategic marketing and commercialization arm of the Agency for Science, Technology and Research (A*STAR) Singapore, manages and consolidates all research institutes' intellectual properties under one roof as a one-stop centre for research institutes, industries and enterprises. Exploit Technologies provides access to Singapore's large pool of intellectual property and knowledge generated by over 2,000 researchers at A*STAR's research institutes.